Veracyte VCYT stock
Veracyte, Inc. · Healthcare · end-of-day data as of Nov 13, 2026
- Price target at$54.14 +122.5%
- ConsensusBuy · 14
- P/E vs own-58.8%
- P/E vs sector-51.0%
- FCF yield+8.2%
- RSI28
- Sector▲ +15.9%
- Earnings in103d
- P/E15.8x
- Support-4.4%
- Resistance+8.5%
- Off 52w high-60.1%
- Volume0.8x
- Bollingerlower half
- News0.00
- Trendsideways
- 52w range$22–$61
- ATR+14.5%
- Off ATH-71.7%
- Insiders-$2.86M
- MAs0 of 4
- MA20×50Death 3d ago
- MACD-2.50
Updates with the 15-min delayed price; analysts, insiders and news are from the last close. Not a forecast or investment advice.
What changed
The stock fell 1.2% that day while healthcare stocks rose.
- Veracyte's 50-day average crossed below its 200-day average on Nov 13, 2026; that was the last session.
- Last close (Nov 13): VCYT -1.2% = market (SPY) -0.4% + Healthcare sector +0.7% + VCYT on its own -1.6%.
Wording by an AI model from pretickt's data; the dated facts under it are the platform's own. Not investment advice.
Analyst price targets and predictions
7 firms with a target in the last 12 months · last close $24.33 · as of Nov 13, 2026
Strong buy 2Buy 9Hold 3Sell 0Strong sell 0
14 analysts in November 2026: 11 rate it a buy or strong buy (79%) and 3 a hold. A year earlier, 75% rated it a buy or strong buy.
Is Veracyte a good stock to buy?
Veracyte is strong on 3 of the 4 questions about the business. The price is low: 15.8 times its earnings, below its 3-year median of 62.1 (Nov 13, 2026). pretickt does not say whether to buy or sell.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.
Snapshot
- P/E15.8x
- P/E vs sector-51.0%
- P/E vs own-58.8%
- Price target at+122.5%
- ConsensusBuy
- Market cap$1.96B
- FCF yield+8.2%
- Insiders-$2.86M
- Earnings in103d
- News0.00
Why it moved
0 stories on the day (30-day average 0.8).
Market = SPY. Sector = equal-weight average of the tracked companies in the same sector, net of the market.
Price and events
Last close $24.33 · -39.0% over 1y · E earnings · D dividend · S split · A analyst rating change
Technicals
- Trendsideways
- Sector▲ +15.9%
- MAs20▼ 50▼ 100▼ 200▼
- Above MAs0 of 4 above
- MA20×50Death 3d ago
- RSI28
- Support-4.4%
- Resistance+8.5%
- Off 52w high-60.1%
- Off ATH-71.7%
- 52w range$24.33
- Bollingerlower half
- MACD-2.50
- ATR+14.5%
- Volume0.8x
Revenue and free cash flow
Q3 FY2026: Revenue +15.1% year over year, free cash flow 25.0% of revenue, operating margin 10.9%.
| Q3 FY2026 | Sep 30, 2026 | $152M | 0.38 | $37.92M | 70.6% | 10.9% | 20.8% |
| Q2 FY2026 | Jun 30, 2026 | $150M | 0.31 | $42.97M | 72.2% | 15.3% | 17.0% |
| Q1 FY2026 | Mar 31, 2026 | $139M | 0.35 | $32.25M | 72.3% | 17.1% | 20.6% |
| Q4 FY2025 | Dec 31, 2025 | $141M | 0.50 | $48.27M | 74.4% | 18.4% | 29.3% |
| Q3 FY2025 | Sep 30, 2025 | $132M | 0.24 | $41.97M | 69.2% | 17.4% | 14.5% |
| Q2 FY2025 | Jun 30, 2025 | $130M | -0.01 | $32.32M | 69.0% | -4.0% | -0.8% |
| Q1 FY2025 | Mar 31, 2025 | $114M | 0.09 | $3.54M | 69.5% | 2.5% | 6.2% |
| Q4 FY2024 | Dec 31, 2024 | $119M | 0.06 | $20.38M | 66.4% | 3.5% | 4.3% |
Peers
| 20D | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 |  | $265.12 | -2.2% | -6.8% | +6.8% | 32.2 | $43.69B | |
| 2 |  | $1,738.91 | +0.5% | -3.7% | -11.9% | 37.7 | $34.59B | |
| 3 |  | $207.01 | -1.2% | -33.1% | +11.2% | 35.6 | $31.3B | |
| 4 |  | $370.48 | -0.5% | -1.2% | +0.8% | 30.4 | $30.08B | |
| 5 |  | $259.60 | 0.0% | -0.9% | -3.8% | 25.9 | $28.56B | |
| 6 |  | $154.39 | -1.7% | -10.1% | -16.1% | 68.3 | $17.24B | |
| 7 |  | $337.97 | -0.8% | -11.0% | -3.7% | 371.4 | $16.19B | |
| 8 | | $24.33 | -1.2% | -60.1% | +122.5% | 15.8 | $1.96B |
Data as of Nov 13, 2026 close.
Latest news
Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.